Allurion Technologies Announces FDA Clearance for Updated Elipse Balloon System in Weight Management

Allurion Technologies, Inc., a leader in non-surgical weight loss solutions, announced today that its updated Elipse Balloon System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The clearance expands the device’s indication for apply in adults with a body mass index (BMI) of 27 to 40 kg/m² who have obesity-related comorbidities, marking a significant step in the company’s mission to provide accessible, minimally invasive options for long-term weight management.

The Elipse Balloon is a swallowable, procedure-free intragastric balloon designed to promote satiety and reduce food intake by occupying space in the stomach for approximately 16 weeks. Unlike traditional intragastric balloons that require endoscopic placement and removal, the Elipse system is ingested in a capsule form and naturally passes through the gastrointestinal tract after the treatment period, eliminating the need for anesthesia, surgery, or follow-up procedures for removal.

How the Elipse Balloon Works

The Elipse Balloon is made of a thin, flexible polyurethane material and is filled with saline once it reaches the stomach. By taking up volume in the gastric cavity, the device helps patients feel fuller faster, thereby reducing caloric intake during meals. Clinical studies have shown that patients using the Elipse Balloon in conjunction with a supervised diet and lifestyle modification program achieve an average weight loss of 10 to 15% of their total body weight over the 16-week treatment period.

This mechanism aligns with current clinical guidelines that recommend multimodal approaches to obesity treatment, combining behavioral interventions, nutritional counseling, and, when appropriate, medical devices or pharmacotherapy. The Elipse Balloon serves as a tool to support adherence to dietary changes during the critical early phases of weight loss.

FDA Clearance and Clinical Evidence

The FDA’s 510(k) clearance was based on data from a multicenter clinical trial involving over 500 participants across the United States and Europe. The study demonstrated that the Elipse Balloon was safe and effective for weight reduction in adults with obesity, with a favorable safety profile. Serious adverse events were rare and primarily related to transient gastrointestinal symptoms such as nausea, vomiting, or abdominal discomfort, which typically resolved within a few days of balloon placement.

Importantly, the trial also showed improvements in obesity-related health markers, including reductions in systolic blood pressure, fasting glucose, and LDL cholesterol levels among participants who completed the program. These findings support the device’s role not only in weight loss but also in improving metabolic health.

The updated version of the Elipse Balloon includes enhancements to the catheter system and balloon material to improve reliability and patient comfort during ingestion and inflation. These refinements were informed by real-world use and feedback from healthcare providers and patients.

Addressing a Growing Public Health Need

Obesity remains a major public health challenge in the United States, affecting more than 42% of adults according to the Centers for Disease Control and Prevention (CDC). It is a leading risk factor for heart disease, stroke, type 2 diabetes, and certain cancers. Despite the availability of lifestyle interventions and bariatric surgery, many individuals face barriers to care, including cost, access, and reluctance to undergo invasive procedures.

Non-surgical options like the Elipse Balloon fill an vital gap in the treatment continuum, particularly for patients with lower BMI thresholds or those who are not candidates for or prefer to avoid surgery. By offering a temporary, reversible intervention that does not require permanent anatomical alteration, the Elipse system supports a personalized approach to weight management.

Availability and Next Steps

Allurion Technologies plans to make the updated Elipse Balloon System available to healthcare providers and patients in the United States beginning in the third quarter of 2026. The company will launch a comprehensive training program for physicians, dietitians, and other healthcare professionals to ensure proper patient selection, counseling, and monitoring throughout the treatment process.

Patients interested in the Elipse Balloon are advised to consult with a qualified healthcare provider to determine if the device is appropriate for their individual health status and weight loss goals. Eligibility criteria include a BMI between 27 and 40 kg/m², presence of at least one obesity-related comorbidity (such as hypertension, type 2 diabetes, or dyslipidemia), and commitment to participating in a structured lifestyle modification program.

Expert Perspective

“The FDA clearance of the Allurion Elipse Balloon represents a meaningful advancement in non-surgical weight management tools,” said Dr. Natalie Singh, MPH, board-certified internal medicine physician and health editor. “By combining a minimally invasive device with behavioral support, we offer patients a scientifically grounded option that can jump-start their weight loss journey while promoting sustainable lifestyle changes. It’s not a magic solution, but for the right patient, it can be a powerful catalyst for long-term health improvement.”

Key Takeaways

• The Allurion Elipse Balloon System has received FDA 510(k) clearance for use in adults with BMI 27–40 kg/m² and obesity-related comorbidities.
• The device is swallowed in capsule form, fills with saline in the stomach, and passes naturally after approximately 16 weeks—requiring no endoscopy or anesthesia.
• Clinical trials show average weight loss of 10–15% of total body weight when combined with diet and lifestyle changes.
• Improvements in blood pressure, glucose, and cholesterol levels were observed in study participants.
• The updated system features design enhancements for improved safety, comfort, and reliability.
• Availability in the U.S. Is expected to begin in Q3 2026.

Frequently Asked Questions

How is the Elipse Balloon placed and removed?

The Elipse Balloon is ingested as a capsule attached to a thin catheter. Once confirmed in the stomach via X-ray, it is filled with saline. After approximately 16 weeks, a time-activated valve opens, allowing the balloon to empty and pass naturally through the digestive tract. No endoscopic procedure is needed for removal.

Who is a good candidate for the Elipse Balloon?

Ideal candidates are adults with a BMI of 27 to 40 kg/m² who have at least one obesity-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol) and are motivated to participate in a supervised diet and lifestyle program. It is not recommended for individuals with certain gastrointestinal disorders, prior stomach surgery, or those who are pregnant or planning pregnancy.

What kind of weight loss results can I expect?

In clinical studies, patients using the Elipse Balloon alongside lifestyle modifications lost an average of 10 to 15% of their total body weight over four months. Individual results vary based on adherence to diet, physical activity, and behavioral support.

Are there side effects?

Common side effects include nausea, vomiting, and abdominal pain, particularly in the first few days after placement. These symptoms are usually mild to moderate and resolve spontaneously or with supportive care. Serious complications are rare but can include pancreatitis, ulcers, or esophageal irritation—highlighting the importance of medical supervision.

Is the Elipse Balloon covered by insurance?

Coverage varies by insurance provider and plan. As a newly cleared device, reimbursement policies are still evolving. Patients are encouraged to check with their insurer and discuss potential costs with their healthcare provider.

Sources: U.S. Food and Drug Administration (FDA) 510(k) Database, Allurion Technologies Press Release (April 20, 2026), Centers for Disease Control and Prevention (CDC) Adult Obesity Facts, ClinicalTrials.gov (Study NCT05512345), Journal of Clinical Endocrinology & Metabolism – “Intragastric Balloons for Weight Management: A Systematic Review” (2025).